Probiotics in human infections
Authors:
Open Access
- 8 October 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 50 (5) , 625-627
Abstract
At the beginning of the last century, the Russian immunologist Elie Metchnikoff argued that life-long intake of yoghurt containing lactic acid-producing microorganisms could explain the differences in length of life between ethnic groups. The idea was that the bacteria in the fermented products competed with microorganisms that are injurious to health.1 Today it is known that the normal human microflora is important as a barrier against colonization by exogenous pathogenic microorganisms and potentially pathogenic bacteria already present in small numbers in the microflora.2 The normal microflora influence several biochemical, physiological and immunological features of the host, particularly the gastrointestinal flora, which consists of the most dense and diverse collection of bacteria.3 Disturbances in the normal microflora can be caused by several things, one being the administration of antimicrobial agents.4 Probiotic microorganisms are thought to counteract disturbances and thereby reduce the risk of colonization by pathogenic bacteria.5 Studies on strains of microorganisms used in probiotic dietary supplements have demonstrated that several strains produce antimicrobial substances such as organic acids, bacteriocins and peptides. In vitro and animal studies have further shown inhibitory effects of probiotic bacteria to be mediated by their interference with the adhesion of gastrointestinal pathogens or with toxins produced by the pathogenic microorganisms. Adjuvant-like effects on intestinal and systemic immunity have also been demonstrated for some strains.6 However, it is important to remember that even closely related strains have heterogeneous qualities.Keywords
This publication has 26 references indexed in Scilit:
- Selection of dairy bacterial strains as probiotics for oral healthEuropean Journal of Oral Sciences, 2002
- The use of probiotics in head and neck infectionsCurrent Infectious Disease Reports, 2002
- Effect of antimicrobial agents on the ecological balance of human microfloraThe Lancet Infectious Diseases, 2001
- Saccharomyces boulardii in Maintenance Treatment of Crohn’s DiseaseDigestive Diseases and Sciences, 2000
- Lactobacillus GG in the prevention of antibiotic-associated diarrhea in childrenThe Journal of Pediatrics, 1999
- Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trialThe Lancet, 1999
- A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian childrenThe Journal of Pediatrics, 1999
- The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patientsJournal of Infection, 1998
- A Randomized Placebo-Controlled Trial of Saccharomyces boulardii in Combination With Standard Antibiotics for Clostridium difficile DiseaseJAMA, 1994
- Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective studyGastroenterology, 1989